News Kamada Ltd.

Stocks

KMDA

IL0010941198

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE 06:44:59 2026-09-04 EDT			5-day change	1st Jan Change
2,491.00 ^ILa	+0.44%		+0.16%	+10.22%

09-03	Kamada Ltd. Obtains Israel Tax Authority Ruling on Withholding Tax Procedures for $9.8 Million Cash Dividend to Shareholders	CI
08-17	Kamada Lowers Quarterly Dividend to $0.17 a Share; Payable Sept. 17 to Holders of Record Aug. 27	MT

All News

Mentions Relevance

09-03	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders	AQ
09-03	Kamada Ltd. Obtains Israel Tax Authority Ruling on Withholding Tax Procedures for $9.8 Million Cash Dividend to Shareholders	CI
08-18	Kamada Declares Cash Dividend of $0.17 per Share, the Company Reported Record-High Revenue and Profitability for First Six Months of 2026	AQ
08-17	Kamada Lowers Quarterly Dividend to $0.17 a Share; Payable Sept. 17 to Holders of Record Aug. 27	MT
08-17	Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026	AQ
08-17	Kamada Ltd. Declares Cash Dividend, Payable on September 17, 2026	CI
08-12	Kamada Ltd., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Kamada Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Kamada's Finance Chief Chaime Orlev to Step Down	MT
08-12	Kamada: Q2 Earnings Snapshot	AQ
08-12	Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance	AQ
08-12	Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2026	CI
08-12	Kamada Announces Planned Transition of Chief Financial Officer	AQ
08-12	Chaime Orle Plans to Resign as Chief Financial Officer of Kamada Ltd, Effective December 31, 2026	CI
08-05	Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026	AQ
07-20	Kamada Ltd Announces Three-Year USD 50 Million Supply Agreement To Supply Plasma To Biopharmaceutical Company Focused On Plasma-Derived Therapies	CI
07-20	Kamada Signs $50 Million Plasma Supply Agreement With Biopharmaceutical Firm	MT
07-20	Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies	AQ
07-13	Kamada Ltd. Highlights CYTOGAM Study Results Presented at The 2026 ISHLT Annual Meeting	CI
07-13	Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting	AQ
06-01	Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory	AQ
06-01	Kamada Announces FDA Approval of Its New In-House Rabies Virus Neutralization Testing Laboratory	CI
05-13	Kamada Ltd., Q1 2026 Earnings Call, May 13, 2026
05-13	Kamada: Q1 Earnings Snapshot	AQ
05-13	Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year	AQ